Medtronic (MDT) Q3 FY2024 earnings: revenue $8.1 billion, up 4.7% on the year
Medtronic plc (MDT) reported revenue of $8.1 billion for Q3 FY2024, the quarter ended 26 January 2024, up 4.7% on the same quarter a year earlier. Net income was $1.3 billion, up 8.2% on the year, and diluted earnings per share $0.99. The figures are the company's own, from the 10-Q it filed with the SEC on 27 February 2024.
Revenue
$8.1 billion
+4.7% on the year · +1.3% on the quarter
Q4 FY2022Q3 FY2024
Operating margin
18.3%
18.0% a year earlier
Q4 FY2022Q3 FY2024
Net income
$1.3 billion
+8.2% on the year · +45.4% on the quarter
Q4 FY2022Q3 FY2024
Diluted EPS
$0.99
+7.6% on the year · +45.6% on the quarter
Q4 FY2022Q3 FY2024
this quarterthe same quarter a year earlierHover a bar for its figure.
Income statement (profit and loss)
$ million
Q3 FY2024
Q2 FY2024
Q3 FY2023
On the quarter
On the year
Last 8 quarters
Revenue
8,089
7,984
7,727
+1.3%
+4.7%
Cost of revenue
2,782
2,761
2,689
+0.8%
+3.5%
Gross profit
5,307
5,223
5,038
+1.6%
+5.3%
Gross margin
65.6%
65.4%
65.2%
Research and development
695
698
688
-0.4%
+1.0%
Selling, general and administrative
2,673
2,686
2,615
-0.5%
+2.2%
Operating income
1,483
1,340
1,392
+10.7%
+6.5%
Operating margin
18.3%
16.8%
18.0%
Interest expense
188
180
167
+4.4%
+12.6%
Pre-tax income
1,472
1,313
1,375
+12.1%
+7.1%
Income tax
135
402
146
-66.4%
-7.5%
Effective tax rate
9.2%
30.6%
10.6%
Net income
1,322
909
1,222
+45.4%
+8.2%
Net margin
16.3%
11.4%
15.8%
Diluted EPS
$0.99
$0.68
$0.92
+45.6%
+7.6%
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
Q3 FY2024
Q2 FY2024
Q3 FY2023
On the quarter
On the year
Last 8 quarters
Operating cash flow
2,474
661
1,574
+274.3%
+57.2%
Capital expenditure
346
461
332
-24.9%
+4.2%
Free cash flow
2,128
200
1,242
+964.0%
+71.3%
Free cash flow margin
26.3%
2.5%
16.1%
Cash from investing
-707
-424
-287
Cash from financing
-1,500
-90.0
-2,134
Depreciation and amortisation
649
672
679
-3.4%
-4.4%
Share-based compensation
85.0
146
81.0
-41.8%
+4.9%
Buybacks
132
226
71.0
-41.6%
+85.9%
Dividends paid
917
918
904
-0.1%
+1.4%
Dividend per share
$0.69
$0.69
$0.68
0.0%
+1.5%
Diluted shares, weighted
1,332m
1,332m
1,332m
-0.0%
-0.0%
Shares outstanding at period end
1,330m
1,330m
1,330m
-0.0%
-0.1%
Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.
Balance sheet
$ million
Q3 FY2024
Q2 FY2024
Q3 FY2023
On the quarter
On the year
Last 8 quarters
Shareholders' equity
51,792
51,460
51,441
+0.6%
+0.7%
Non-controlling interest
204
187
177
+9.1%
+15.3%
Debt
25,182
25,080
28,128
+0.4%
-10.5%
Finance lease liabilities
56.0
56.0
55.0
0.0%
+1.8%
Other liabilities
13,602
13,304
14,333
+2.2%
-5.1%
Total liabilities and equity
90,836
90,087
94,134
+0.8%
-3.5%
Fixed assets
5,838
5,735
5,437
+1.8%
+7.4%
Goodwill
41,160
40,821
41,565
+0.8%
-1.0%
Intangible assets
13,690
14,060
15,265
-2.6%
-10.3%
Investments
6,698
6,423
6,616
+4.3%
+1.2%
Cash and equivalents
1,623
1,311
4,521
+23.8%
-64.1%
Receivables
5,968
5,934
5,887
+0.6%
+1.4%
Inventory
5,726
5,754
5,375
-0.5%
+6.5%
Other assets
10,133
10,049
9,468
+0.8%
+7.0%
Total assets
90,836
90,087
94,134
+0.8%
-3.5%
Questions
What was Medtronic's revenue in Q3 FY2024?
Medtronic (MDT) reported revenue of $8.1 billion for Q3 FY2024, the quarter ended 26 January 2024, up 4.7% on the same quarter a year earlier.
How much did Medtronic earn in Q3 FY2024?
Net income for Q3 FY2024 was $1.3 billion, up 8.2% on the year, and diluted earnings per share $0.99.
When did Medtronic report Q3 FY2024 results?
Medtronic filed its 10-Q for the quarter ended 26 January 2024 with the SEC on 27 February 2024.
Each quarter as filed, linked to its filing. Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.
10-Q for the period ended 26 January 2024, filed 27 February 2024: the filing.